These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1. Zsebik B; Citri A; Isola J; Yarden Y; Szöllosi J; Vereb G Immunol Lett; 2006 Apr; 104(1-2):146-55. PubMed ID: 16384610 [TBL] [Abstract][Full Text] [Related]
8. Nucleolin-binding by ErbB2 enhances tumorigenicity of ErbB2-positive breast cancer. Wolfson E; Goldenberg M; Solomon S; Frishberg A; Pinkas-Kramarski R Oncotarget; 2016 Oct; 7(40):65320-65334. PubMed ID: 27542246 [TBL] [Abstract][Full Text] [Related]
9. p130Cas/Cyclooxygenase-2 axis in the control of mesenchymal plasticity of breast cancer cells. Bisaro B; Montani M; Konstantinidou G; Marchini C; Pietrella L; Iezzi M; Galiè M; Orso F; Camporeale A; Colombo SM; Di Stefano P; Tornillo G; Camacho-Leal MP; Turco E; Taverna D; Cabodi S; Amici A; Defilippi P Breast Cancer Res; 2012 Oct; 14(5):R137. PubMed ID: 23098208 [TBL] [Abstract][Full Text] [Related]
10. HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance. Huang X; Wang S; Lee CK; Yang X; Liu B Cancer Lett; 2011 Aug; 307(1):72-79. PubMed ID: 21497990 [TBL] [Abstract][Full Text] [Related]
11. Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancer. Dokmanovic M; Hirsch DS; Shen Y; Wu WJ Mol Cancer Ther; 2009 Jun; 8(6):1557-69. PubMed ID: 19509242 [TBL] [Abstract][Full Text] [Related]
12. Cooperative antitumor activities of carnosic acid and Trastuzumab in ERBB2 D'Alesio C; Bellese G; Gagliani MC; Aiello C; Grasselli E; Marcocci G; Bisio A; Tavella S; Daniele T; Cortese K; Castagnola P J Exp Clin Cancer Res; 2017 Nov; 36(1):154. PubMed ID: 29100552 [TBL] [Abstract][Full Text] [Related]
13. PC cell-derived growth factor stimulates proliferation and confers Trastuzumab resistance to Her-2-overexpressing breast cancer cells. Kim WE; Serrero G Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4192-9. PubMed ID: 16857791 [TBL] [Abstract][Full Text] [Related]
14. Protein tyrosine kinase 6 promotes ERBB2-induced mammary gland tumorigenesis in the mouse. Peng M; Ball-Kell SM; Tyner AL Cell Death Dis; 2015 Aug; 6(8):e1848. PubMed ID: 26247733 [TBL] [Abstract][Full Text] [Related]
15. The ErbB2 signaling network as a target for breast cancer therapy. Badache A; Gonçalves A J Mammary Gland Biol Neoplasia; 2006 Jan; 11(1):13-25. PubMed ID: 16947083 [TBL] [Abstract][Full Text] [Related]
16. ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines. Ginestier C; Adélaïde J; Gonçalvès A; Repellini L; Sircoulomb F; Letessier A; Finetti P; Geneix J; Charafe-Jauffret E; Bertucci F; Jacquemier J; Viens P; Birnbaum D Oncogene; 2007 Nov; 26(50):7163-9. PubMed ID: 17525746 [TBL] [Abstract][Full Text] [Related]
17. Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions. Liu B; Fan Z; Edgerton SM; Yang X; Lind SE; Thor AD Cell Cycle; 2011 Sep; 10(17):2959-66. PubMed ID: 21862872 [TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904 [TBL] [Abstract][Full Text] [Related]
19. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis. Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418 [TBL] [Abstract][Full Text] [Related]
20. Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer. Pályi-Krekk Z; Barok M; Isola J; Tammi M; Szöllosi J; Nagy P Eur J Cancer; 2007 Nov; 43(16):2423-33. PubMed ID: 17911008 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]